Katharine E. Spink
Directeur des opérations chez Dark Horse Consulting Group, Inc.
Profil
Katharine E.
Spink is currently the Chief Operating Officer & Managing Partner at Dark Horse Consulting Group, Inc. She previously worked as the Program Director at Cardiovascular Disease Foundation, Inc. from 2007 to 2008, as the VP-Regenerative Medicine Programs Operations at Geron Corp.
from 2003 to 2011, and as the Chief Operating Officer & Vice President at Asterias Biotherapeutics, Inc. from 2013 to 2018.
Spink received her undergraduate degree from Rice University and her doctorate from Stanford University School of Medicine.
Postes actifs de Katharine E. Spink
| Sociétés | Poste | Début |
|---|---|---|
Dark Horse Consulting Group, Inc.
 Dark Horse Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Dark Horse Consulting Group, Inc. develops cell and gene therapy products. The firm offers process development, custom device development, project and program management, financing and diligence, manufacturing support and preclinical development services. The company was founded by Anthony H. Davies in 2014 and is headquartered in Campbell, CA. | Directeur des opérations | 01/01/2018 |
Anciens postes connus de Katharine E. Spink
| Sociétés | Poste | Fin |
|---|---|---|
| ASTERIAS BIOTHERAPEUTICS INC | Directeur des opérations | 19/01/2018 |
| Cardiovascular Disease Foundation, Inc. | Corporate Officer/Principal | 01/01/2008 |
| GERON CORPORATION | Directeur des opérations | - |
Formation de Katharine E. Spink
| Rice University | Undergraduate Degree |
| Stanford University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GERON CORPORATION | Health Technology |
| Entreprise privées | 3 |
|---|---|
Asterias Biotherapeutics, Inc.
 Asterias Biotherapeutics, Inc. BiotechnologyHealth Technology Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA. | Health Technology |
| Cardiovascular Disease Foundation, Inc. | |
Dark Horse Consulting Group, Inc.
Dark Horse Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Dark Horse Consulting Group, Inc. develops cell and gene therapy products. The firm offers process development, custom device development, project and program management, financing and diligence, manufacturing support and preclinical development services. The company was founded by Anthony H. Davies in 2014 and is headquartered in Campbell, CA. | Commercial Services |